P-055 - High BIM mRNA levels associated with longer survival in advanced gastric cancer

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Gastric Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter N. Wu
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors N. Wu1, B. Liu1, J. Wei1, L. Yu1, A. Gimenez-Capitan1, J. Sanchez2, R. Rosell1
  • 1Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing/CN
  • 2Department of Preventive Medicine and Public Health, Madrid/ES



5-fluorouracil,oxaliplatin, and docetaxel chemotherapy are commonly used in the treatment for gastric cancer (GC). Apoptosis relevant genes might be associated with drug resistance. Approximately half of the patients could be the candidates for second-line treatment at the time of failure to first-line chemotherapy. Docetaxel is among the most frequently used agents for gastric second-line treatment


We investigated mRNA expression levels of BIM, AEG-1 and AXL in 131advanced gastric cancer samples and correlated gene levels with patients' overall survival. All 131 patients received first-line FOLFOX chemotherapy, in which 56 patients were further treated with second-line docetaxel-based chemotherapy.


Correlation between BIM mRNA expression and AEG-1 mRNA expression was observed (rs =0.30, P = 0.002). There is no association between mRNA expression levels of any of the individual genes and overall survival in patients only receiving first-line FOLFOX chemotherapy. In a subgroup of patients receiving docetaxel-based second-line chemotherapy, those with high or intermediate levels of BIM obtained a median overall survival of 18.2 months (95% CI = 12.8-23.6), compared with 9.6 months (95% CI = 8.9-10.3) in patients with low BIM levels (P = 0.008). However, there was no correlation between AEG-1, AXL mRNA expression and overall survival. The risk of mortality was higher in patients with low BIM mRNA levels compared with high or intermediate levels (HR = 2.61, 95% CI = 1.21-5.62, P = 0.01).


BIM could be considered as a biomarker to identify whether patients can benefit from docetaxel-based second-line chemotherapy in gastric cancer.